[go: up one dir, main page]

WO2014126254A1 - Vecteur d'expression de protéine de liaison à une membrane - Google Patents

Vecteur d'expression de protéine de liaison à une membrane Download PDF

Info

Publication number
WO2014126254A1
WO2014126254A1 PCT/JP2014/053730 JP2014053730W WO2014126254A1 WO 2014126254 A1 WO2014126254 A1 WO 2014126254A1 JP 2014053730 W JP2014053730 W JP 2014053730W WO 2014126254 A1 WO2014126254 A1 WO 2014126254A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cell
target protein
membrane
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2014/053730
Other languages
English (en)
Japanese (ja)
Inventor
恵 黒川
恵奈 山口
梨沙 小川
正義 塚原
洋子 林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of WO2014126254A1 publication Critical patent/WO2014126254A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Definitions

  • the present invention provides a target protein expression vector, target protein, or target protein capable of simultaneously expressing a target protein and a target protein fused with a membrane-binding domain or a fragment of the target protein using one gene.
  • the present invention relates to a method for screening a cell that expresses a fragment, a cell that highly produces a target protein, a method for producing a cell that highly produces a target protein, and a method for producing the target protein using the cell.
  • Non-patent Document 1 In the production of protein drugs such as cytokines, growth factors, hormones, and antibodies using mammalian cells as hosts, it is important to select and screen high-producing cells simply and rapidly for shortening the drug development period.
  • conventional selection of target protein producing cells has the following three problems. (1) Disagreement between cells with drug resistance phenotype and cells expressing the target protein Currently, cells producing the target protein have host cells with the drug resistance marker gene incorporated in the same expression vector as the target protein or in another expression vector. As a result, the cells are indirectly screened by selecting cells having a drug-resistant phenotype (Non-patent Document 1).
  • the expression of the drug resistance gene does not necessarily match the expression of the target protein. That is, a cell exhibiting a drug resistance trait does not always express the target protein at a high level. Therefore, select a cell population based on drug resistance traits, and measure the amount of the target protein directly using the enzyme-linked immuno-sorbent assay (ELISA) method for cells that highly express the target protein. Thus, the protein producing cells must be rescreened (Non-patent Document 2). Since cell selection is performed in a process with two or more steps, screening time and labor are required.
  • the expressed drug resistance marker protein is an impurity protein that is unnecessary in the production of the target protein. That is, when the target protein is used as a pharmaceutical, it is necessary to remove this drug resistance marker protein in the purification process. Furthermore, it has been reported that high expression of a drug resistance marker protein used for cell selection changes the metabolism of the host cell and conversely reduces the expression of the target protein (Non-patent Document 3). In addition, fluorescent proteins are generally used as marker proteins for cell selection, but are known to have cytotoxicity, and improvements to fluorescent proteins with low toxicity are being promoted (Patent Document 1).
  • SFACS fluorescence-activated cell sorter
  • flow cytometry flow cytometry
  • the cell sorter can select cells in the state of individual clones.
  • cell selection marker genes examples include green fluorescent protein and red fluorescent protein (Non-patent Document 4).
  • the expression of the fluorescent protein does not necessarily match the expression of the target protein. That is, as described in (1), cells that highly express the fluorescent protein do not necessarily express the target protein at a high level.
  • Patent Document 2 a method in which a target protein and a fluorescent protein are fused and expressed in the same gene cassette.
  • the activity and quality of the target protein may be affected.
  • it is not a practical protein production method because of concerns such as antigenicity.
  • IRES internal ribosome entry site
  • Patent Document 4 a method has been reported in which the target protein is expressed on the cell membrane of the production cell and the expression level of the target protein is directly detected using a cell sorter.
  • a protein expression vector in which a polypeptide for cell membrane binding is arranged immediately downstream of the stop codon of the target protein is introduced into a host cell, and the protein is translated by treating the cell with an aminoglycoside antibiotic.
  • the target protein expressed on the cell membrane can be expressed by reducing the recognition of the termination codon by the translation initiation factor complex (read-through). Is detected with a cell sorter, and it is reported that cells expressing the target protein can be selected.
  • a target protein expression vector for efficiently and mass-producing a protein composition and safely manufacturing a protein drug, a cell into which the expression vector is introduced, and a method for producing the target protein using the cell .
  • the present invention relates to the following (1) to (13).
  • a target protein expression vector comprising a DNA sequence encoding a target protein including a splicing donor sequence, a polypyrimidine sequence, a splicing acceptor sequence, and a DNA sequence encoding a transmembrane region in this order.
  • An expression vector for the protein of interest in order.
  • mRNA messenger RNA
  • B A cell in which at least 1 ⁇ 10 3 molecules / cell of a protein in which the target protein or a fragment of the target protein and the transmembrane region are fused is expressed.
  • a screening method for cells that produce a target protein in a high amount comprising detecting the target protein or a fragment of the target protein expressed on the cell membrane of the cell according to (3) or (4).
  • a method for producing the cell according to (3) or (4) comprising the steps of culturing the cell according to (3) or (4), accumulating the target protein in a culture solution, and purifying the target protein from the cell culture solution.
  • Simultaneous expression of both the target protein and the target protein or a protein in which the target protein fragment and the transmembrane region are fused including the step of introducing the target protein expression vector described in (1) into a host cell How to make.
  • a A cell in which messenger RNA (mRNA) encoding a protein in which a target protein or a fragment of the target protein is fused with a transmembrane region is expressed in 0.1% to 5% of the total mRNA of the target protein.
  • mRNA messenger RNA
  • a cell in which mRNA encoding a target protein or a protein in which a fragment of the target protein is fused with a transmembrane region is expressed in 0.1% to 2% of the total mRNA of the target protein.
  • a cell in which 1 ⁇ 10 3 to 1 ⁇ 10 7 molecules / cell of a protein in which the target protein or a fragment of the target protein and the transmembrane region are fused is expressed.
  • a screening method for cells that produce a target protein in a high amount comprising detecting the target protein or a fragment of the target protein expressed on the cell membrane of the cell according to (9) or (10).
  • (12) A method for producing the cell according to (9) or (10).
  • (13) A method for producing a target protein comprising the steps of culturing the cell according to (9) or (10), accumulating the target protein in a culture solution, and purifying the target protein from the cell culture solution.
  • an expression vector for a target protein that can simultaneously express a target protein and a protein in which the target protein or a fragment of the target protein and a transmembrane region are fused using one gene, It is possible to provide a method for screening cells to be expressed, a cell that produces a target protein at a high level, a method for producing a cell that produces a target protein at a high level, and a method for producing the target protein using the cell.
  • FIG. 2 shows a schematic diagram of a human antibody expression vector pINC_OX40L / CD98H vector containing DNA fragments encoding the anti-human OX40 antibody L chain and the anti-human CD98 / LAT1 antibody H chain.
  • CMV is the CMV promoter
  • Poly A is the BGH polyadenylation site
  • Hc is the anti-human CD98 / LAT1 complex antibody heavy chain
  • Lc is the anti-human OX40 antibody light chain
  • SV is the SV40 polyadenylation site.
  • CHX-r represents a cycloheximide resistance gene, respectively.
  • DNA fragment encoding anti-human CD98 / LAT1 antibody H chain including anti-human OX40 antibody L chain, splicing donor (SD) sequence, first bovine growth factor (BGH) polyadenylation signal sequence, polypyrimidine sequence Of the secreted human antibody and membrane-bound human antibody expression vector pINC_TMSP_AC27, including DNA sequences encoding (poly-Pyr), splicing acceptor (SA) sequence, platelet ⁇ derived growth factor receptor (PDGFR) transmembrane region (PDGFRtm) A schematic diagram is shown.
  • CMV is the CMV promoter
  • Poly A is the BGH polyadenylation site
  • Hc is the anti-human CD98 / LAT1 complex antibody heavy chain
  • Lc is the anti-human OX40 antibody light chain
  • SV is the SV40 polyadenylation site.
  • CHX-r represents a cycloheximide resistance gene
  • TM represents PDGFRtm.
  • pINC_TMSP_AC27 the downstream of the platelet derived growth factor receptor membrane region (PDGFRtm) from the DNA fragment (Hc) encoding the H chain of the CD98 / LAT1 antibody.
  • Hc is the anti-human CD98 / LAT1 complex antibody heavy chain
  • SD is the splicing donor sequence
  • polyA is the BGH polyadenylation signal sequence
  • T / C25 is the 25-base polypyrimidine sequence consisting of thymine and cytosine.
  • SA represents a splicing acceptor sequence
  • TM represents PDGFRtm.
  • Including anti-human OX40 antibody L chain DNA fragment encoding anti-human CD98 / LAT1 antibody H chain containing SD sequence, 1st BGH-polyA sequence, poly-Pyr sequence, SA sequence, including DNA sequence encoding PDGFRtm,
  • CMV is the CMV promoter
  • Poly A is the BGH polyadenylation site
  • Hc is the anti-human CD98 / LAT1 complex antibody heavy chain
  • Lc is the anti-human OX40 antibody light chain
  • SV is the SV40 polyadenylation site.
  • CHX-r represents a cycloheximide resistance gene
  • TM represents PDGFRtm
  • Tol2-L represents a left-end Tol2 transposon
  • Tol2-R represents a right-end Tol2 transposon.
  • the correlation between the antibody concentration of the secretory antibody (mg / L) and the fluorescence intensity when stained with a PE-conjugated anti-human IgG mouse antibody when CHO-K1 cells transformed with the pINC_TMSP_AC27 vector are cultured is shown.
  • the vertical axis represents the fluorescence intensity (FI)
  • the horizontal axis represents the antibody concentration (mg / L) of the culture supernatant.
  • A The gate diagram developed by forward scatter (FS) and side scatter (SS) in flow cytometer (FCM) analysis is shown.
  • B Fluorescence intensity due to binding of PE-conjugated anti-human mouse antibody is shown on the horizontal axis, and the number of counts on the vertical axis. The horizontal line represents the 0.1% fraction of the total count.
  • the analysis result of the antibody H chain mRNA expression level of the CHO-K1 cell into which the secreted / membrane-bound human antibody-expressing Tol2 transposon vector AC10 / TnPMug, AC17 / TnPMug, or AC27 / TnPMug vector was introduced is shown.
  • A shows the mRNA expression level of the membrane-bound human antibody H chain in each cell when the expression in the cell into which the AC10 / TnPMug vector is introduced is 1.
  • (C) shows the ratio (%) of the mRNA expression level of the membrane-bound human antibody H chain in the mRNA expression level of all antibody H chains.
  • a schematic diagram of a membrane-bound Fab fragment encoded by a membrane-bound Fab fragment expression vector is shown.
  • VH is the heavy chain variable region
  • CH1-3 is the heavy chain constant region
  • SD is the region corresponding to the splicing donor sequence
  • SA is the region corresponding to the splicing acceptor sequence
  • PDGFRtm is the platelet derived growth factor
  • Each of the receptor (PDGFR) transmembrane regions is shown.
  • a protein in which a target protein and a transmembrane region are fused is defined as a membrane-bound protein.
  • a protein in which a fragment of a target protein and a transmembrane region are fused is defined as a fragment of a membrane-bound protein.
  • the DNA sequence consists of adenine, thymine, guanine and cytosine bases and is abbreviated as A, T, G and C, respectively.
  • the RNA sequence consists of adenine, uracil, guanine and cytosine bases and is abbreviated as A, U, G and C, respectively.
  • the expression vector means a DNA in which exogenous DNA is incorporated and can increase in the introduced host cell, and may be simply described as a vector.
  • the vector includes a nucleic acid sequence having a gene expression control region necessary for expressing foreign DNA and a sequence encoding a target protein. Examples of the gene expression control region include enhancers, promoters, and terminators.
  • splicing refers to a splicing donor sequence (abbreviated as SD), a branch site (branch site), and a splicing acceptor sequence (splicing acceptor sequence) present in a messenger ⁇ RNA (mRNA) precursor (pre-mRNA).
  • SD splicing donor sequence
  • branch site branch site
  • splicing acceptor sequence messenger ⁇ RNA (mRNA) precursor
  • pre-mRNA messenger ⁇ RNA
  • SA refers to a reaction in which an intron is excluded from an exon by a cleavage-binding reaction by a spliceosome reaction that is a complex of RNA and protein.
  • Examples of the expression vector of the present invention include an expression vector containing a DNA sequence encoding a target protein and a DNA sequence encoding a transmembrane region, which are cis-actuated on one gene.
  • a protein membrane-bound protein or membrane-bound protein fragment
  • mRNA messenger RNA
  • the expression vector of the present invention include an expression vector comprising a DNA sequence encoding a target protein including a splicing donor sequence, a polypyrimidine sequence, a splicing acceptor sequence, and a DNA sequence encoding a transmembrane region in this order. . More specifically, such an expression vector of the present invention, more specifically, a DNA encoding a target protein containing a splicing donor sequence present at the 5 ′ end of a stop codon (TAG, TAA or TGA) of the DNA sequence encoding the protein. An expression vector comprising a DNA sequence encoding a sequence, a polypyrimidine sequence, a splicing acceptor sequence and a transmembrane region.
  • the splicing donor sequence may be a naturally occurring sequence or an artificially inserted sequence.
  • artificial splicing is performed by designing the codon of the amino acid sequence encoded by the inserted splicing donor sequence and the codon of the target protein to match.
  • Donor sequences can be inserted into expression vectors.
  • the expression vector of the present invention includes a DNA sequence encoding a protein containing a splicing donor sequence, a first polyadenylation signal sequence, a polypyrimidine sequence, a splicing acceptor sequence, and a DNA sequence encoding a transmembrane region in this order. Also included are expression vectors. Further, the expression vector of the present invention includes a DNA sequence encoding a protein containing a splicing donor sequence, a first polyadenylation signal sequence, a polypyrimidine sequence, a splicing acceptor sequence, a DNA sequence encoding a transmembrane region, and a second sequence. An expression vector containing a polyadenylation signal sequence in order is mentioned.
  • the expression vector of the present invention includes a DNA sequence encoding a polyadenylation signal sequence, a polypyrimidine sequence, a splicing acceptor sequence and a transmembrane region on the 3 ′ end side of a DNA sequence encoding a protein containing a splicing donor sequence. And an expression vector containing.
  • the expression vector when animal cells are used as a host, any of those capable of functioning in animal cells can be used. For example, pcDNAI, pCDM8 (manufactured by Funakoshi), pAGE107 [JP-A-3-22979].
  • CMV cytomegalovirus
  • SV40 early promoter SV40 early promoter
  • retrovirus promoter metallothionein promoter
  • heat shock promoter SR ⁇ promoter
  • moloney murine leukemia virus promoter And enhancers moloney murine leukemia virus promoter And enhancers.
  • an IE gene enhancer of human CMV may be used together with a promoter.
  • the expression vector of the present invention When the expression vector of the present invention is introduced into a cell, it generates a mature mRNA encoding a membrane-bound protein or the membrane-bound protein fragment by a splicing reaction simultaneously with the generation of a mature mRNA encoding the protein. Can do.
  • the splicing donor sequence may be any of a sequence that exists in nature and is known to function as a splicing donor sequence, and an artificially created splicing donor sequence, such as M (A / G / T) GGT (A / G) (A / T) (A / G) (A / T) -containing sequence (M is A or C), preferably GTA (A / T) GT-containing sequence, Examples include sequences containing GTATGT and sequences containing M (A / G) GGT (A / G) A (A / G) T (M is A or C) (US Pat. No. 6,642,028).
  • the splicing donor sequence includes a sequence containing CAGGTAAGT (SEQ ID NO: 1), a sequence containing GACGTAAGT (SEQ ID NO: 2) (Lucas et al., Nucleic Acids Research, 24, 1774-1779, 1996.), CGGGTAAAT And a sequence containing (SEQ ID NO: 3).
  • the homology with the above consensus sequence is 80% or more, 90% or more, 95% or more, and A splicing donor sequence that causes a splicing reaction can also be used in the present invention.
  • the immunoglobulin constant region includes a sequence containing a naturally occurring splicing donor sequence, and the immunoglobulin constant region can also be applied as a splicing donor.
  • examples of the splicing acceptor sequence include a sequence containing N (C / T) AGG (N may be any nucleotide).
  • Specific examples of the splicing acceptor sequence include a sequence containing CAGAA (SEQ ID NO: 4) and a sequence containing GCAGG (SEQ ID NO: 5).
  • the splicing acceptor sequence may function even if the sequence is slightly different from the above consensus sequence, the homology with the above consensus sequence is 80% or more, 90% or more, 95% or more, A splicing acceptor sequence that causes a splicing reaction can also be used in the present invention.
  • a branch site exists between the splicing donor sequence and the splicing acceptor sequence.
  • branch site examples include a sequence containing (C / T) N (C / T) T (A / G) A (C / T) (N may be any nucleotide), and 3 'of the splicing donor sequence. Exists on the side. Specific examples include sequences including CATTAACT, TCCTAAT, and the like.
  • a polypyrimidine sequence (hereinafter sometimes abbreviated as Poly-Pyr) is a sequence in which bases consisting of C and / or T, which are pyrimidine bases, are continuous between the splicing donor sequence and the branch site. To do.
  • the number of consecutive pyrimidine bases in the polypyrimidine sequence in the present invention may be 8 bases or more, but preferably 8-30 bases, 9-30 bases, 10-30 bases, 11-30 bases, 12 Examples include lengths of -30 bases, 13-30 bases, 15-30 bases, more preferably 15-29 bases, 15-28 bases, 15-27 bases, 15-26 bases and 15-25 bases.
  • Specific examples of the Poly-Pyr sequence include the nucleotide sequences represented by SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8.
  • the polypyrimidine sequence is present between the splicing donor sequence and the splicing acceptor sequence and between the polyadenylation sequence and the splicing acceptor sequence.
  • the expression vector of the present invention includes a first polyadenylation signal sequence and a second polyadenylation signal sequence
  • the polypyrimidine sequence is present between the first polyadenylation signal sequence and the splicing acceptor sequence.
  • the membrane-bound type produced by splicing after the mRNA encoding the target protein transcribed from the introduced vector Both the protein and the mRNA encoding the membrane-bound protein fragment are simultaneously expressed, and both the secreted protein and the membrane-bound protein or the membrane-bound protein fragment are expressed.
  • the sP / mP ratio can be controlled. Specifically, when the poly-Pyr sequence is shortened, the splicing reaction efficiency decreases, and when the poly-Pyr sequence is lengthened, the splicing reaction efficiency increases.
  • an amino acid sequence derived from any protein can be used as the transmembrane region as long as the protein penetrates the cell membrane or is anchored to the cell membrane.
  • the transmembrane region used in the present invention may be any of 1 to 12 transmembrane membrane proteins or GPI anchor proteins (European Patent Publication No. 1716233), such as a cell membrane ligand (or precursor ligand), Examples include a transmembrane region derived from a membrane protein selected from a cell membrane receptor, a T cell receptor, an adhesion molecule, a major histocompatibility complex (MHC), a membrane immunoglobulin and a GPI anchor protein.
  • MHC major histocompatibility complex
  • Cell membrane ligands include epidermal growth factor (EGF) ligand family, EGF, transforming growth factor- ⁇ (TGF- ⁇ ), amphiregulin, betacellulin, epiregulin, heparin-binding epidermal growth factor-like growth factor (HB-EGF ), Transmembrane regions such as NTAK, vascular endothelial growth factor (VEGF) and heregulin (neuregulin), FAS ligand, TRAIL ligand.
  • EGF epidermal growth factor
  • TGF- ⁇ transforming growth factor- ⁇
  • amphiregulin betacellulin
  • betacellulin epiregulin
  • HB-EGF heparin-binding epidermal growth factor-like growth factor
  • NTAK vascular endothelial growth factor
  • VEGF vascular endothelial growth factor
  • neutral protein TRAIL
  • Cell membrane receptors include EGF receptor (EGFR), insulin-like growth factor receptor I (IGF-IR), hepatocyte growth factor receptor (HGFR, cMet), platelet derived growth factor receptor (PDGFR), vascular endothelial growth Transmembrane regions such as VEGFR), amino acid transporters, tetraspanin-type proteins, G-protein coupled receptors (GPCR), and Cluster of differentiation (CD) antigens.
  • EGF receptor EGF receptor
  • IGF-IR insulin-like growth factor receptor I
  • HGFR hepatocyte growth factor receptor
  • cMet hepatocyte growth factor receptor
  • PDGFR platelet derived growth factor receptor
  • VEGFR vascular endothelial growth Transmembrane regions
  • amino acid transporters amino acid transporters
  • tetraspanin-type proteins tetraspanin-type proteins
  • GPCR G-protein coupled receptors
  • CD Cluster of differentiation
  • MHC examples include MHC class I and class II transmembrane regions.
  • Membrane immunoglobulins include transmembrane regions of membrane-bound IgM, IgD, IgG, IgE and IgA antibodies (Peterson et al., PNAS, 83, 8883-8887, 1986, Rebecca et al., 32, 277-285, 1995, Tsurushita and Korn et al., Mol. Cell Biol., 1987, 7, 2602-2605).
  • the transmembrane region of the present invention include the PDGFR transmembrane region.
  • the DNA encoding the transmembrane region include a DNA comprising the base sequence represented by SEQ ID NO: 12.
  • the polyadenylation signal (hereinafter abbreviated as polyA) may be any polyadenylation signal as long as it contains an AATAAA consensus sequence and can be polyadenylated, and specifically, siman virus 40 (SV40) late polyadenylation signal (Scheck et al., Mol.
  • the same sequence may be used, or two different types of poly A signals may be used.
  • the DNA encoding the target protein in the present invention is a DNA sequence encoding the amino acid sequence of the full-length protein or a partial fragment of the protein, and starting from the start codon (ATG) to the stop codon (TAA, TAG or TGA) Say.
  • a full-length protein or a partial fragment of the protein may be a functional protein or a simple structural protein.
  • a DNA encoding a protein containing a splicing donor sequence is a DNA sequence encoding a target protein containing a splicing donor sequence that exists in nature in the DNA sequence encoding the amino acid sequence of the target protein.
  • Examples of the DNA sequence encoding the target protein include a splicing donor sequence artificially inserted in the DNA sequence encoding the amino acid sequence, and any of them may be used.
  • a DNA sequence encoding a target protein including a splicing donor a DNA sequence having a splicing donor sequence at the 5 ′ end side of the stop codon of the full length or partial fragment of the target protein to be expressed, and a purpose to be expressed Examples thereof include a DNA sequence in which a splicing donor sequence is artificially inserted at the 5 ′ end side of the stop codon of the full-length protein or a partial fragment.
  • the codon of the DNA sequence into which the SD sequence is inserted matches the codon encoding the amino acid sequence of the target protein, and the codon of the DNA sequence generated as a result of the splicing reaction is a membrane.
  • the splicing donor sequence so as to match the codon of the amino acid sequence of the bound protein, a vector that simultaneously expresses the target protein and the membrane-bound protein or a fragment of the membrane-bound protein can be prepared.
  • an immunoglobulin fragment when expressed as a membrane-bound protein fragment, it can be carried out by introducing a splicing donor sequence into the antibody constant region.
  • the antibody constant region may be any of a CH1 domain, a hinge domain, a CH2 domain, and a CH3 domain, and preferred examples include insertion of a splicing donor sequence into the CH2 domain.
  • a secretory antibody and a Fab fragment spliced with the CH2 domain and fused to the transmembrane region are expressed on the cell membrane of the cell into which the vector has been introduced. be able to.
  • the codon encoding the 51st glycine of the IgG2 antibody CH2 domain was replaced from GGC to GGT, and the codon encoding the 6th glycine of the IgG2 antibody CH2 domain was replaced from GGG to GGT SD sequence in which the codon encoding the 86th glycine of the CH2 domain of IgG1 antibody is replaced from GGC to GGT, and the codon encoding the 48th tyrosine of the CH2 domain of IgG1 antibody is changed from TAC to TAT.
  • Examples include substituted SD sequences.
  • the splicing donor sequence may be naturally occurring in an immunoglobulin constant region or an artificial sequence, depending on the target protein to be expressed and the membrane-bound protein or the membrane-bound protein fragment. In addition, it may be designed by inserting it at any position as long as it is at the 5 ′ end side of the stop codon in the target protein.
  • the protein in the present invention refers to a protein produced using the above-described expression vector.
  • the protein composition refers to a composition containing protein molecules produced and purified by the protein production method of the present invention.
  • a protein composition includes a protein composition that includes two or more different variations of post-translational modifications.
  • Protein post-translational modifications include SS-linked cross-linking of amino acid side chains, glycosylation (N-linked sugar chains, O-linked sugar chains), phosphorylation, sulfation, methylation, myristoylation, and peptide chain specificity
  • the protein composition in the present invention is a composition containing any degree of post-translational modification protein as long as it is a modified protein variation within a range acceptable as a protein pharmaceutical obtained by the protein production method of the present invention. Also good.
  • the target protein may be any protein as long as it can be expressed as a membrane-bound protein and protein using the expression vector of the present invention.
  • examples include human serum proteins, albumin binding proteins, peptide hormones, growth factors, cytokines, blood clotting factors, fibrinolytic proteins, antibodies, membrane proteins, and partial fragments of various proteins.
  • human intravenous immunoglobulin IVIG
  • EPO erythropoietin
  • albumin growth hormone
  • FSH follicle stimulating hormone
  • HGF hepatocyte growth factor
  • IFN interferon
  • Fas ligand blood coagulation factor
  • II, VII, VIII, IX, X prothrombin
  • fibrinogen protein C
  • protein S protein S
  • antithrombin III tissue plasminol
  • tissue plasminol examples include a gene activator (tPA), a monoclonal antibody, an oligoclonal antibody, and a polyclonal antibody.
  • Examples of the monoclonal antibody in the present invention include monoclonal antibodies and gene recombinant antibodies produced from hybridomas.
  • Examples of the recombinant antibody include a chimeric antibody, a humanized antibody [also referred to as a complementarity determining region (CDR) transplanted antibody], a human antibody, and the like.
  • the monoclonal antibody in the present invention is an antibody secreted by antibody-producing cells of a single clone, recognizes only one epitope (also called an antigenic determinant), and has a uniform amino acid sequence (primary structure) constituting the monoclonal antibody. It is.
  • Oligoclonal antibodies and polyclonal antibodies are antibody mixtures containing two or more monoclonal antibodies.
  • Antibody molecules are also called immunoglobulins (hereinafter referred to as Ig), and human antibodies are classified into IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, and IgM isotypes according to the difference in molecular structure. Is done. IgG1, IgG2, IgG3, and IgG4 having relatively high amino acid sequence homology are collectively referred to as IgG.
  • Antibody molecules are composed of polypeptides called heavy chains (hereinafter referred to as H chains) and light chains (hereinafter referred to as L chains).
  • the H chain is the H chain variable region (also referred to as VH) and the H chain constant region (also referred to as CH) from the N terminal side
  • the L chain is also expressed as the L chain variable region (VL) from the N terminal side.
  • L chain constant region also referred to as CL.
  • CH H chain variable region
  • CH H chain constant region
  • CL L chain constant region
  • ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ chains are known for each subclass.
  • CH is further composed of each domain of the CH1 domain, hinge domain, CH2 domain, and CH3 domain from the N-terminal side.
  • a domain refers to a functional structural unit constituting each polypeptide of an antibody molecule.
  • the CH2 domain and the CH3 domain are collectively referred to as Fc region or simply Fc.
  • C ⁇ chain and C ⁇ chain are known.
  • examples of the fusion protein in the present invention include those obtained by fusing different protein fragments with an appropriate linker or the like.
  • an Fc fusion protein also referred to as an immunoadhesin
  • an Fc fusion protein in which multiple Fc regions are fused an Fc fusion protein in which multiple Fc regions are fused
  • GST glutathioneathS-transferase
  • FLAG fusion protein FLAG fusion protein
  • Histidine tag fusion protein green fluorescence protein (GFP) fusion protein and the like
  • GFP green fluorescence protein
  • Fc region Fc variant
  • Fc variant containing an amino acid residue modification that has been modified to enhance or lack the effector activity of the antibody, stabilize the antibody, and control the blood half-life. It can be used for an antibody expressed by the expression vector of the invention.
  • examples of the protein in the present invention include bispecific antibodies and multivalent antibodies (WO1998 / 050431, WO2001 / 7734, WO2002 / 002773, WO2009 / 131239).
  • the protein fragment in the present invention may be either a functional fragment or a structural fragment of a protein, particularly an antibody fragment.
  • antibody fragments include Fab, Fab ′, F (ab ′) 2 , single chain Fv (scFv), diabody, dsFv, peptides containing multiple CDRs (particularly peptides containing 6 CDRs of VH and VL), etc. Can be mentioned.
  • Examples of the cell of the present invention include a cell into which the above-described expression vector is introduced, and specifically includes a cell into which the expression vector of the present invention has been introduced.
  • the cell can simultaneously express both a membrane-bound protein or the membrane-bound protein fragment and a target protein.
  • the cell of the present invention is a cell into which the expression vector of the present invention has been introduced, and an mRNA encoding a target protein transcribed from the vector and an mRNA encoding a membrane-bound protein generated by splicing after transcription.
  • 0.1% or more of the cells express mRNA that encodes a membrane-bound protein.
  • the mRNA expression ratio (%) of the membrane-bound protein to the total mRNA of the protein of interest is 0.1-5%, 0.1
  • the range of ⁇ 4%, 0.1 to 3%, and 0.1 to 2% is preferable, but the range of 0.5 to 2% is preferable, more preferably 1 to 2%, 1.1 to 2%, 1.2 to 2%, and 1.3 to 2%. 1.4 to 2% range.
  • a cell into which the protein expression vector of the present invention has been introduced can simultaneously express both the target protein and a membrane-bound protein or a fragment of the membrane-bound protein, and the membrane-bound protein is expressed on the cell membrane. Yes.
  • the target protein is a secretory protein
  • a range is preferable.
  • the expression level of the membrane-bound protein or the fragment of the membrane-bound protein is a conjugate (chemical substance, antibody, protein ligand, etc.) that specifically binds to the membrane-bound protein or the fragment of the membrane-bound protein.
  • the expression level may be any level as long as it can be detected by binding analysis using a cell, and can be measured by methods such as Cell binding ELISA, flow cytometer (FCM), FMAT8100HTS system (Applied Biosystems).
  • the cell of the present invention include a cell expressing 1 ⁇ 10 3 molecules / cell or more of a membrane-bound protein or a fragment of the membrane-bound protein on the cell membrane.
  • As the expression level of the membrane-bound protein or the fragment of the membrane-bound protein on the cell membrane cells expressing 1 ⁇ 10 3 to 1 ⁇ 10 7 molecules / cell are preferable.
  • the expression level of the mRNA encoding the membrane-bound protein or the fragment of the membrane-bound protein is preferably expressed by about 0.1% to 2% of the total protein mRNA (sum of the expression levels of sP-mRNA and mP-mRNA). Cell.
  • any cell generally used for recombinant protein production such as animal cells, plant cells, and microorganisms
  • examples of cells into which the expression vector of the present invention is introduced include Chinese hamster ovary tissue-derived CHO cells, human cell PER.C6, human leukemia cell Namalwa cell, monkey cell COS, rat myeloma cell line YB2 / 3HL.P2.G11.16Ag.
  • mouse myeloma cell line NS0 cell mouse myeloma cell line SP2 / 0-Ag14 cell
  • Syrian hamster kidney tissue-derived BHK cell human Burkitt lymphoma-derived Namalva cell
  • human retinoblastoma-derived PER.C6 cell human embryonic Examples include kidney tissue-derived HEK293 cells, human myeloid leukemia-derived NM-F9 cells, embryonic stem cells, and fertilized egg cells.
  • a host cell for producing a recombinant glycoprotein pharmaceutical an embryonic stem cell or a fertilized egg cell used for producing a transgenic non-human animal producing the recombinant glycoprotein pharmaceutical, and a recombinant sugar Examples include plant cells used to produce transgenic plants that produce protein drugs.
  • NS0 cell parent cell lines include NS0 cells described in literature such as BIO / TECHNOLOGY, 10, 169 (1992), Biotechnol. Bioeng., 73, 261, (2001).
  • NS0 cell line (RCB0213) registered in RIKEN Cell Bank, or sub-strains obtained by acclimating these strains to various serum-free media are also included.
  • SP2 / 0-Ag14 cells examples include J. Immunol., 126, 317, (1981), Nature, 276, 269, (1978), Human Antibodies and Hybridomas, 3, 129, (1992), etc. SP2 / 0-Ag14 cells described in the above.
  • SP2 / 0-Ag14 cells (ATCC CRL-1581) registered in ATCC or sub-strains (ATCC CRL-1581.1) in which these strains are conditioned to various serum-free media are also included.
  • the parent cell of the rat myeloma cell line YB2 / 3HL.P2.G11.16Ag.20 cell includes a cell line established from Y3 / Ag1.2.3 cell (ATCC CRL-1631). Specific examples thereof include YB2 / 3HL.P2.G11.16Ag.20 cells described in J. CellBiol., 93, 576 (1982), Methods Enzymol. 73B, 1 (1981) and the like. Can be mentioned. In addition, YB2 / 3HL.P2.G11.16Ag.20 cells (ATCC CRL-1662) registered in ATCC or sub-strains obtained by acclimating these strains to various serum-free media are also included.
  • the amount of fucose that binds ⁇ 1,6 to N-acetylglucosamine G (GlcNAc) present at the reducing end of the N-glycoside-linked sugar chain that binds to the antibody Fc region is reduced or eliminated.
  • Cells can also be used.
  • the cell is a cell in which at least one enzyme associated with a series of fucose metabolic reactions is reduced or deficient.
  • protein such as an enzyme involved in synthesis of intracellular sugar nucleotide GDP-fucose or N-acetylglucosamine at the reducing terminal of N-glycoside-linked complex sugar chain is located at position 1 of fucose at ⁇ -position.
  • proteins such as enzymes involved in modification of the sugar chain to be bound, proteins involved in transport of intracellular sugar nucleotide GDP-fucose to the Golgi apparatus, and the like.
  • Examples of cells in which these activities are reduced or deleted include CHO cells in which the ⁇ 1,6-fucose transferase (FUT8) gene is reduced or deleted (WO2005 / 035586, WO02 / 31140), lentil lectin LCA, pea lectin PSA , Cells that have acquired resistance to lectins such as broad bean lectin VFA or yellow chawantake lectin AAL (WO02 / 31140), Lec13 [Somatic Cell and Molecular genetics, with reduced GMD-mannose-4,6-dehydratase (GMD) activity, 12, 55 (1986)], cells with reduced GMD activity, cells with reduced or deficient GDP-fucose transporter (WO2003 / 85102) and the like.
  • FUT8 ⁇ 1,6-fucose transferase
  • Mammalian cells used in the present invention are suspended in a culture solution without adhering to a cell culture support in a serum-free medium not containing fetal calf serum (hereinafter referred to as FCS). Cells that can survive and proliferate are preferred, and mammalian cells that can float and survive and proliferate in a protein-free medium without protein are more preferred.
  • the tissue culture incubator for confirming mammalian cells that can survive in a serum-free medium may be any incubator as long as it is a flask, petri dish or the like that is coated with an adhesion culture.
  • the suspension mammalian cell used in the present invention may be a cell originally adapted to suspension culture having suspension properties, or a suspension in which adhesive mammalian cells are adapted to suspension culture conditions. Any mammalian cell may be used.
  • the “floating mammalian cell obtained by acclimatizing an adherent mammalian cell to a floating culture condition” is, for example, according to the method described in Mol. Biotechnol., 2000, 15 (3), 249-257, etc. It can be produced by establishing cells that exhibit the same proliferation and viability as before suspension culture acclimation or better than those before acclimation to suspension culture (J. Biotechnol., 2007, 130 (3), 282-290).
  • any method for introducing an expression vector into cells any method can be used as long as it introduces DNA into animal cells.
  • electroporation [Cytotechnology, 3, 133 (1990)]
  • calcium phosphate method (specialized) Kaihei 2-227075)
  • a method using calcium ions [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972), Gene, 17, 107 (1982), Molecular & General Genetics, 168, 111 (1979)]
  • the lipofection method Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)].
  • Examples of the method for expressing the target protein of the present invention include a method in which the expression vector of the present invention is introduced into a host cell and both the target protein and the membrane-bound protein or a fragment of the membrane-bound protein are expressed simultaneously.
  • the method of expressing the protein of the present invention can be used to select cells expressing a membrane-bound protein without expressing a drug selection marker gene or an unnecessary fusion protein and without selecting a drug. it can. As a result of selecting a cell that highly expresses a membrane-bound protein or a fragment of the membrane-bound protein, a cell that highly expresses the target protein can be obtained.
  • a desired plurality of target proteins such as a full length (or partial fragment) of the target protein and a membrane-bound protein can be simultaneously obtained. It can also be expressed.
  • membrane-bound target protein fragments include antibody Fab fragments when the target protein is an antibody.
  • Fab fragments can be expressed by artificial insertion of splicing donor sequences anywhere in the antibody constant region.
  • the Fab fragment can be expressed particularly by inserting an artificial splicing donor sequence in the CH2 domain.
  • Examples of the method for producing the target protein of the present invention include a method of introducing the expression vector of the present invention into a host cell and producing the target protein using the cell.
  • Examples of the method for producing a target protein of the present invention include a method for producing a target protein including the following steps (a) to (e). (a) Introducing into a host cell a protein expression vector comprising a DNA sequence encoding a protein containing a splicing donor sequence, a polyadenylation signal sequence, a polypyrimidine sequence, a splicing acceptor sequence and a DNA sequence encoding a transmembrane region. Process.
  • the expression vector of the present invention is introduced into a host cell, and a cell that highly expresses a membrane-bound protein or a fragment of the membrane-bound protein is obtained.
  • a screening method is included. As a result of selecting cells that highly express a membrane-bound protein or a fragment of the membrane-bound protein by this screening method, cells that produce the target protein at a high level can be obtained.
  • Animal cell culture media include RPMI1640 medium (Invitrogen), GIT medium (Nippon Pharmaceutical), EX-CELL301 medium (JRH), EX-CELL302 medium (JRH), IMDM medium (Invitrogen) ), Hybridoma-SFM medium (Invitrogen), CD-CHO medium (Invitrogen), EX-CELL 325-PF medium (SAFC Biosciences) and SFM4CHO medium (HyClone) it can. It can also be obtained by blending and preparing necessary sugars, amino acids, etc. in animal cell culture media.
  • static culture can be performed in a 5% CO 2 atmosphere at a culture temperature of 37 ° C. It can also be cultured by methods such as Wave bioreactor (GE Healthcare Bioscience), swirl stirrer, bioreactor culture [Cytotechnology, (2006), 52: 199-207] it can.
  • Cells expressing the membrane-bound protein of the present invention or a fragment of the membrane-bound protein are detected using a compound or protein that specifically binds to the expressed membrane-bound protein or the fragment of the membrane-bound protein. can do. Any of them can be used as long as it binds to a membrane-bound protein or a fragment of the membrane-bound protein.
  • a fluorescent protein (FITC, TRITC, etc.) can be used as a ligand protein, a receptor protein, a polyclonal antibody, a monoclonal antibody and an antigen protein.
  • PE such as Cy-5
  • an enzyme peroxidase, alkaline phosphatase
  • biotin with a radioactive substance (3 H, 14 C, 32 P, 35 S, 67 Ga, 99 Tc) detector conjugated etc.
  • a radioactive substance 3 H, 14 C, 32 P, 35 S, 67 Ga, 99 Tc
  • cells expressing a membrane-bound protein or a fragment of the membrane-bound protein can be detected.
  • the target protein to be expressed or the fragment of the target protein is a human IgG antibody or the antibody fragment
  • an anti-human IgG antibody, protein A / G or an antigen specifically recognized by the human IgG antibody is conjugated with an appropriate detection substance
  • the membrane-bound human IgG antibody can be detected using the resulting product.
  • the target protein to be expressed is a TNFR-Fc fusion protein
  • a membrane-bound TNFR is prepared using a TNF- ⁇ , anti-Fc antibody or protein A / G conjugated with an appropriate detection substance.
  • -Fc fusion protein can be detected.
  • the present invention includes a method for analyzing the protein modification ability and modification characteristics of a cell producing the target protein. That is, a cell into which a secretory / membrane-bound protein expression vector has been introduced expresses a membrane-bound protein or the membrane-bound protein fragment on the cell membrane and produces a secreted protein. By analyzing the degree of protein modification of the expressed membrane-bound protein or the membrane-bound protein fragment, the protein modification ability and modification characteristics of the cell can be identified.
  • Proteins are modified as a result of post-translational modifications such as sugar chains, amino groups, carboxyl groups, phosphoric acid, and sulfuric acid bound to the protein.
  • the protein modification level can be directly analyzed using a substance that specifically binds to a modified residue of the membrane-bound protein or the membrane-bound protein fragment, and the protein on the cell membrane can be analyzed with an enzyme or the like. It can also be analyzed indirectly by analyzing the free protein by releasing it by digesting with.
  • the protein modification is a sugar chain modification
  • it is specific to the sugar chain structure, such as a protein (lectin) that specifically binds to each sugar chain binding structure, an anti-sugar chain antibody, a ligand protein, a receptor protein, a low molecular weight compound, etc. Any one may be used as long as it is coupled.
  • a method for analyzing the sugar chain-modifying ability and sugar chain-modifying properties of protein-producing cells by the above-described method is also included in the present invention. By this method, a target protein-producing cell capable of producing a specific sugar chain structure of the target protein can be screened and obtained.
  • a detection method measurement using a method described in monoclonal antibody-Principles-and-practice, Third-edition, Academic Press (1996), monoclonal antibody experiment manual (Kodansha Scientific 1987), and specifically enzyme Examples include -linked immunosorbent assay (ELISA), fluorescence-activated cell sorter (FACS) analysis using flow cytometer (FCM) method, and fluorescence staining using FMAT8100HTS system (Applied Biosystems). Further, by sorting cells that highly express a membrane-bound protein using FACS or the like, that is, cells having high fluorescence intensity, a high protein-producing cell can be obtained more directly.
  • ELISA -linked immunosorbent assay
  • FACS fluorescence-activated cell sorter
  • FCM flow cytometer
  • FMAT8100HTS system Applied Biosystems
  • the method for measuring secretory protein in the present invention examples include the above-mentioned ELISA method, sandwich ELISA method, Biacore system using surface plasmon resonance (SPR) method, measurement method using high performance liquid chromatography (HPLC), and the like. It is done.
  • the target protein can be purified using affinity chromatography, ion exchange chromatography, ultrafiltration, gel filtration, or the like.
  • antibodies are purified from the culture supernatant of transformants using protein A-columns [Monoclonal Antibodies-Principles and practice, Third edition, Academic Press (1996), Antibodies-A Laboratory Manual, Cold Spring Harbor Laboratory (1988) )].
  • methods used in protein purification such as gel filtration, ion exchange chromatography and ultrafiltration can be combined.
  • vector capable of simultaneously expressing secretory antibody and membrane-bound antibody (hereinafter abbreviated as secretory / membrane-bound antibody expression vectors) pINC_TMSP_AC27, pINC_TMSP_AC17 and pINC_TMSP_AC10 It was produced as follows.
  • the prepared gene fragment was inserted into an appropriate position of the pINC vector to prepare an expression vector pINC_OX40L / CD98H containing DNA encoding the anti-OX40 antibody L chain and the anti-CD98 / LAT1 complex antibody H chain (FIG. 1).
  • an antibody comprising the L chain of an anti-OX40 antibody and the H chain of an anti-CD98 / LAT1 antibody is abbreviated as a human IgG antibody).
  • BGH-PolyA bovine growth hormone polya Denylation signal sequence
  • T / C sequence 25 25-base polypyrimidine sequence consisting of thymine and cytosine
  • SA sequence acceptor sequence
  • PDGFR platelet-derived growth factor receptor
  • PCR polymerase chain reaction
  • synthetic DNA primers TM-F1 SEQ ID NO: 14
  • TM-R1 SEQ ID NO: 15
  • the synthetic DNA primers TM-F1 and TM-R3 SEQ ID NO: 17
  • a DNA fragment in which the DNA sequence encoding the transmembrane region (SEQ ID NO: 12) was bound to the 3 ′ end of the human antibody H chain was prepared.
  • DNA fragment and the pINC_OX40L / CD98H vector were treated with restriction enzymes BgIII and EcoRI, respectively, and the DNA sequence encoding the PDGFR transmembrane region was found at the 3 ′ end of the DNA sequence encoding the human antibody H chain.
  • a membrane-bound human IgG antibody expression vector pINC_TM vector containing the inserted DNA fragment was prepared.
  • PCR reaction was performed using the synthetic DNA primers AC27-F (SEQ ID NO: 18) and TMSP-R (SEQ ID NO: 19), T / C sequence 25 (SEQ ID NO: 8), SA sequence (SEQ ID NO: 5), a DNA fragment (SEQ ID NO: 11) containing PDGFRtm and BGH-PolyA sequences was prepared.
  • the first BGH-PolyA sequence the DNA encoding the human antibody H chain including the SD sequence, by inserting the prepared DNA fragment into the DNA encoding the human antibody H chain of the pINC_OX40L / CD98H expression vector treated with the restriction enzyme EcoRV , A secreted / membrane-bound human antibody expression vector pINC_TMSP_AC27 containing a poly-Pyr sequence (T / C sequence 25), an SA sequence, a PDGFRtm sequence, and a second BGH-PolyA sequence in order was prepared (FIG. 2).
  • poly-Pyr sequence T / C25 (SEQ ID NO: 8) on the 3 ′ end side of the first BGH-PolyA sequence is replaced with a 15-base poly-Pyr sequence T / C15 (SEQ ID NO: 7) consisting of T and C.
  • secreted / membrane-bound human IgG antibody expression vectors pINC_TMSP_AC17 and pINC_TMSP_AC10 substituted with 8-base poly-Pyr sequence T / C8 (SEQ ID NO: 6), respectively, were prepared.
  • the conjugated human IgG antibody expression vector is a Chinese hamster ovary cell line CHO-K1 (American Type Culture Collection, Cat. No. CCL) using a gene introduction reagent LipofectAmine (registered trademark) 2000 (Life Technologies) according to the attached manual. -61).
  • CHO-K1 cells that became 70-80% confluent in a 100 mm culture plate were washed with serum-free medium and then ⁇ -minimum essential medium medium (hereinafter referred to as MEM medium) (Life Technologies) Was added.
  • MEM medium serum-free medium
  • 24 ⁇ g of secreted / membrane-bound human IgG antibody expression vector pINC_TMSP_AC27 and 60 ⁇ L of LipofectAmine (registered trademark) 2000 solution were mixed and added to the cells, followed by static culture in a 37 ° C., 5% CO 2 incubator for 6 hours was done.
  • the medium was replaced with MEM medium supplemented with 10% fetal bovine serum (hereinafter abbreviated as FCS) (SAFC Biosciences), and diluted appropriately so that the cells did not exceed 90% confluence.
  • FCS fetal bovine serum
  • ⁇ 10 6 cells / mL of cells using phosphate buffer saline (hereinafter abbreviated as PBS) (Life Technologies).
  • PBS phosphate buffer saline
  • a suspension was prepared.
  • 50 ⁇ L of mouse Anti-Human IgG (Fc) -PE (hereinafter referred to as “anti-human IgG mouse antibody”) (BECKMAN, Cat. No. 736007) was added to the cell suspension and reacted at room temperature for 1 hour. After the reaction, the cell suspension was centrifuged, and the cells were washed with PBS to remove excess anti-human IgG mouse antibody. Next, after centrifugation, 10 mL of MEM medium was added to the cells and suspended, and the cell suspension diluted stepwise to 1 cell / well was dispensed into a 96-well plate.
  • the fluorescence intensity of the cells contained in each well was measured using a cell image analysis system (Olympus CELAVIEW RS100). As a result, wells containing multiple cells were visually excluded, and wells where fluorescence was not detected were also excluded. Wells in which fluorescence was detected at 1 cell / well were selected. The cells were cultured until the cells in the selected wells were approximately 90% confluent, and the antibody concentration in the secreted culture medium was measured. The antibody concentration in the culture was measured using HPLC (Waters).
  • the cells into which the expression vector pINC_TMSP_AC27 containing the DNA sequence encoding the human antibody H chain containing the SD sequence, the first BGH-PolyA sequence, the poly-Pyr sequence, the SA sequence, the PDGFRtm and the second BGH-PolyA sequence are introduced on the cell membrane It was revealed that a membrane-bound human IgG antibody can be expressed at the same time and a secretory IgG antibody can be expressed simultaneously in the culture supernatant. It was also revealed that the amount of membrane-bound human IgG antibody expressed on the cell membrane increased with a positive correlation with the amount of secreted human IgG antibody.
  • the anti-human IgG mouse antibody also bound to CHO-K1 cells into which any of the expression vectors pINC_TMSP_AC10, pINC_TMSP_AC17 and pINC_TMSP_AC27 was introduced. Further, IgG antibody was detected in the culture supernatant. Therefore, it was revealed that an expression vector containing a polypyrimidine sequence having a length of 8 bases or more can express both a secretory IgG antibody and a membrane-bound IgG antibody at the same time.
  • the fluorescence intensity of the membrane-bound IgG antibody expressed on the cell membrane is higher than that of cells introduced with pINC_TMSP_AC27 whose poly-Pyr sequence is 25 bases. It was low. Therefore, splicing efficiency from mRNA encoding secretory human IgG antibody to mRNA encoding membrane-bound IgG antibody is reduced in cells introduced with pINC_TMSP_AC10, which has a shorter poly-Pyr sequence than pINC_TMSP_AC27. It was revealed.
  • the pINC_TMSP_AC27 expression vector produced in Example 1 (2) was treated with restriction enzymes SalI and NotI, and human IgG antibody L chain , Including a human H chain containing an SD sequence linked under CMV-derived enhancer / promoter control, a DNA fragment containing the first BGH-polyA, SA sequence and PDGFRtm, and a cycloheximide resistance gene linked under CMV-derived enhancer / promoter control The gene fragment was excised.
  • PCR was performed using the purified gene fragment as a template and the synthetic DNA primers AC27-TnPMug FW (SEQ ID NO: 20) and AC27-TnPMug RV P2 (SEQ ID NO: 21), and restriction enzyme sites SalI and MluI A gene fragment to which was added was prepared.
  • Tol2 transposon vector excluding the antibody L chain, CMV promoter, DNA encoding cassette encoding H chain and cycloheximide resistance gene expression cassette contained in the anti-M2 antibody expressing Tol2 transposon vector described in WO2010 / 143698 (hereinafter referred to as TnPMug vector and the abbreviated) was treated with the restriction enzymes SalI and MluI, the gene fragments generated by PCR in-Fusion TM Advantage PCR Cloning Kit (Clontech , Inc., according to catalog number.
  • TnPMug vector A secreted / membrane-bound human IgG antibody-expressing Tol2 transposon vector AC27 / TnPMug inserted between the enzyme sites SalI and MluI and introduced in a Tol2 transposase-dependent manner was prepared (FIG. 3).
  • TnPMug and AC10 / TnPMug were prepared.
  • the cell suspension is suspended by adding 20 mL of CD opti CHO medium (Life Technologies) containing 200 mM L-Glutamine (hereinafter referred to as cell culture medium) to a 6-well plate. After dispensing at 3 mL / well, the cells were statically cultured for 24 hours in a 37 ° C., 5% CO 2 incubator. After the culture, stirring culture was performed in a 37 ° C., 5% CO 2 incubator for 10 days.
  • CD opti CHO medium Life Technologies
  • cell culture medium 200 mM L-Glutamine
  • CHO-K1 cells introduced with AC27 / TnPMug were centrifuged at 1000 ⁇ rpm for 5 minutes, and the supernatant was removed. Then, 10 ⁇ L (1 ⁇ g) PE-labeled anti-human IgG mouse antibody (mouse Anti-Human IgG (Fc ) -PE, Cat. No.736007, manufactured by BECKMAN), and the mixture was allowed to react for 30 to 60 minutes under light shielding at ice temperature. After the reaction, after washing with a cell culture medium, the cells were collected by centrifugation at 1000 rpm for 5 minutes, and washed twice to remove non-specifically bound PE-labeled anti-human IgG mouse antibody. . After washing, the cells were stirred with 1 mL of cell culture medium and filtered through a tube with a cell strainer.
  • PE-labeled anti-human IgG mouse antibody mouse Anti-Human IgG (Fc ) -PE, Cat. No.736007, manufactured by BECK
  • the membrane-bound antibody retains the binding epitope of the anti-human IgG antibody and the recombinant protein A that binds to the Fc region of the antibody, and a plurality of detection bodies that detect the membrane-bound antibody produce the antibody of the present invention. It was also revealed that it can be applied to cell screening.
  • Membrane-bound human antibody expression level on the cell membrane of antibody-producing cells Secretion / membrane-bound human antibody expression Tol2 transposon vector AC27 / TnPMug having 25, 15 or 8 bases contained in the polypyrimidine sequence, The amount of membrane-bound human antibody expressed on the cell membrane in CHO-K1 cells into which AC17 / TnPMug or AC10 / TnPMug was introduced was examined.
  • Each vector was introduced into CHO-K1 cells in the same manner as in Example 4 (1), and cells expressing membrane-bound human antibodies were measured by the same method as in Example 4 (2) (b). .
  • the recombinant / protein-binding human antibody-expressing Tol2 transposon vector AC27 / TnPMug, AC17 / TnPMug, or AC10 / TnPMug was significantly recombinant protein A Fluorescence intensity increased due to / G-FITC binding. Therefore, as in Example 2, it was revealed that the membrane-bound human antibody was expressed in the secretory / membrane-bound human antibody-expressing Tol2 transposon vector-introduced cells.
  • a secretory / membrane-bound human antibody expression vector containing a polypyrimidine sequence of 8 bases or more is capable of expressing a membrane-bound human antibody, and is a secreted / membrane-bound antibody comprising a polypyrimidine sequence of 15 bases or more. It has been clarified that the human antibody expression vector can highly efficiently express a membrane-bound human antibody.
  • Sorted cells were seeded in a 384-well plate containing 50 ⁇ L of cell culture medium, and statically cultured at 37 ° C. in a 5% CO 2 incubator for 2 weeks. After culturing, the cells that formed colonies were transferred to a 96-well plate in which a cell culture medium was dispensed at 150 ⁇ L / well, followed by stationary culture at 37 ° C. in a 5% CO 2 incubator for 1 week. After culturing, the culture supernatant was collected, and the expression level of the secretory antibody was quantified by the sandwich method (LENCE TM, PerkinElmer) using FRET (fluorescence resonance energy transfer) (FIGS. 6 (a), (b) and (c)).
  • sandwich method LENCE TM, PerkinElmer
  • FRET fluorescence resonance energy transfer
  • Example 4 (2) Secretory / membrane-bound human antibody-expressing Tol2 transposon vectors AC27 / TnPMug, AC17 / TnPMug, and AC10 / TnPMug Introducing cells into cells
  • (a) AC27 / TnPMug, AC17 / TnPMug
  • 8 clones in AC27 / TnPMug-introduced cells 16 in AC17 / TnPMug-introduced cells
  • 6 in AC10 / TnPMug-introduced cells Obtained a single clone.
  • the average antibody production amount of each cell was AC10 / TnPMug ⁇ AC17 / TnPMug ⁇ AC27 / TnPMug.
  • the CHO-K1 cell line expressing membrane-bound human antibodies is cultured, the expression level of membrane-bound human antibodies is examined for each clone, and the most antibody is expressed among the clones into which each expression vector has been introduced. Selected clones. The production amount of the human antibody of the antibody-expressing cell line into which each finally selected expression vector was introduced was examined. Using a production medium with CD opti CHO (Life Technologies) plus L-Glutamine (Life Technologies), seed 1 ⁇ 10 6 cells / 3 mL in a 6-well plate (Corning) at 37 ° C. Then, stirring culture was performed in a 5% CO 2 incubator for 7 days. The IgG antibody concentration was measured by HPLC (Waters) (Table 3).
  • CHO-K1 cells into which the secreted / membrane-bound human antibody-expressing Tol2 transposon vectors AC10 / TnPMug, AC17 / TnPMug, and AC27 / TnPMug were respectively introduced were 0.1 ⁇ g / L in the culture supernatant after 7 days of culture. , 0.5 g / L and 0.4 g / L secretory human IgG antibodies were produced.
  • cells transfected with the AC17 / TnPMug or AC27 / TnPMug vector produced antibodies 5 or 4 times higher than cells transfected with the AC10 / TnPMug vector.
  • antibody-producing cells can be cleaned from cells into which secreted / membrane-bound antibody expression vectors have been introduced using the expression level of membrane-bound antibody as an indicator, and antibody production can be performed using the selected cells. became.
  • the antibody-producing cells selected based on the high expression level of the membrane-bound antibody produced a high amount of secretory antibody.
  • an expression vector containing an 8-base poly-Pyr sequence was introduced into a cell into which an expression vector containing a 15-base poly-Pyr sequence was introduced.
  • the cell-bound antibody is highly expressed, and the cells that are screened using the high expression of the membrane-bound antibody as a marker show high expression of the secretory antibody. It became clear that Thus, it has also been clarified that by introducing an expression vector containing a poly-Pyr sequence of 15 bases or more into a host cell, a high antibody-producing cell can be produced more efficiently and the antibody can be produced.
  • RNA expression in secretory / membrane-bound human antibody-producing cells To analyze the expression of secretory human IgG antibody and membrane-bound human antibody mRNA in cells into which secreted / membrane-bound human antibody expression vectors have been introduced.
  • the mRNA expression of CHO-K1 cells selected in Example 5 (2) using membrane-bound human IgG antibody expression as an index was analyzed by real-time PCR.
  • Total RNA was extracted from cultured cells containing the secreted / membrane-bound human antibody expression vector using the RNeasy (registered trademark) Mini Kit (250) (Cat. No. 74106, QIAGEN) according to the attached instructions. Extracted.
  • probe 3 Fw primer (SEQ ID NO: 22) and probe 3 Rv primer (SEQ ID NO: 23) for amplifying partial fragments of membrane-bound human antibody H chain mRNA, membrane-bound human antibody and PCR of each mRNA fragment was performed using probe 1 Fw primer (SEQ ID NO: 24) and probe 1 Rv primer (SEQ ID NO: 25) for amplifying partial fragments of H chain mRNA of both secretory human antibodies (Fig. 7).
  • the amplified fragment was detected using probe 3 (SEQ ID NO: 26) and probe 1 (SEQ ID NO: 27).
  • AC27 / TnPMug vector-introduced cell membrane-bound antibody H chain mRNA expression level is 23 fold and membrane-bound antibody H in AC27 / TnPMug vector-introduced cell with 25 T / C poly-Pyr sequences
  • the mRNA expression level of the strand was 27 times (FIG. 8 (a)).
  • the total antibody H chain mRNA amount including secreted human antibody H chain and membrane-bound human antibody H chain is AC17 / TnPMug when the mRNA expression level of all antibody H chains in AC10 / TnPMug vector-introduced cells is 1.
  • the H chain mRNA expression level of the vector-introduced cells was doubled, and the H chain mRNA expression level of the AC27 / TnPMug vector-introduced cells was 1.4 times (FIG. 8 (b)).
  • the membrane-bound human antibody H chain mRNA expression level in the total antibody H chain mRNA expression level in each vector-introduced cell was 0.1%, 1.4% or 1.6%, respectively (FIG. 8 (c)).
  • the pre-mRNA encoding the antibody H chain is present in the downstream region and the splicing donor sequence at the 3 ′ end of the antibody H chain. Splicing occurs in the splicing acceptor sequence and expresses both mRNA encoding the membrane-bound human antibody H chain in which the antibody H chain and the PDGFR transmembrane region are fused and mRNA encoding the secreted human antibody H chain. (Figs. 8 (a) and (b)).
  • sequences of secretory antibody mRNA and membrane-bound mRNA expressed in the cells are shown in SEQ ID NO: 28 and SEQ ID NO: 30, and the amino acid sequences encoded by the respective mRNAs are shown in SEQ ID NOs: 29 and 31.
  • cells into which the secretory / membrane-bound human antibody expression vector has been introduced may express membrane-bound human antibody H chain mRNA at a rate of 0.1% or more of the total human antibody H chain mRNA expression level.
  • antibody-producing cells can be obtained by screening with the expression level of membrane-bound antibody (FIG. 8 (c)).
  • the mRNA expression level of membrane-bound human antibody H chain is higher than cells transfected with AC10 / TnMug vector (Figs. 8 (a) and (c))
  • an efficient splicing reaction is performed and mRNA expression of membrane-bound human antibodies is increased. It was revealed that
  • Fab fragment splicing vector (1) Production of secretory / membrane-bound antibody expression vector 4D5TM_Hc Encoding the heavy chain amino acid sequence of anti-HER2 humanized antibody trastuzumab (Herceptin (registered trademark)) (US Pat. No. 5,821,337) The DNA sequence to be inserted was inserted into a Tol2 transposon vector, and a secreted / membrane-bound antibody expression vector 4D5TM_Hc containing the polypyrimidine sequence T / C25 was prepared in the same manner as in Example 3. On the other hand, a DNA sequence encoding a light chain amino acid sequence (US Pat. No.
  • Each Fab fragment expression construct Fab, Fab1, Fab2, and Fab3 produced SD sequences by introducing mutations into genes encoding the following amino acids (FIG. 9).
  • the codon encoding the 51st glycine of the CH2 domain of Fab: IgG1 antibody was replaced from GGC to GGT.
  • the codon encoding the 6th glycine of the CH2 domain of Fab1: IgG1 antibody was replaced from GGG to GGT.
  • the codon encoding the 86th glycine of the CH2 domain of Fab2: IgG1 antibody was replaced from GGC to GGT.
  • the codon encoding the 48th tyrosine of the CH2 domain of Fab3: IgG1 antibody was replaced from TAC to TAT.
  • Membrane-bound Fab fragment expression vector 4D5TM_Fab was prepared by PCR using QuikChange II Site-Directed Mutagenesis Kit (Invitrogen) using 4D5TM_Hc as a template and primers having DNA sequences described in SEQ ID NOs: 32-35 (Table 1). Four). Further, membrane-bound Fab fragment expression vectors 4D5TM_Fab1, 4D5TM_Fab2 and 4D5TM_Fab3 are 4D5TM_Fab as a template, DNA sequence primers set forth in SEQ ID NOs: 36-39, DNA set forth in SEQ ID NOs: 36, 37, 40 and 41, respectively. The primers were prepared in the same manner as described above using the primers for the sequences and the DNA sequences described in SEQ ID NOs: 42 and 43 (Table 4).
  • the antibody-producing cells obtained in Example 8 (1) above were subjected to Fed-batch culture, and the amount of antibody production was examined.
  • the production medium was prepared by adding L-Glutamine (Life Technologies) and soybean hydrolyzate (SAFC) to CD opti CHO (Life Technologies).
  • the Feed medium was prepared by mixing CHO CD EFFICIENTFEED A (Invitrogen) and CHO CD EFFICIENTFEED B (Invitrogen) in equal amounts and adding Glucose (Wako) and Glutamine (Wako).
  • cells expressing membrane-bound IgG, membrane-bound Fab, or membrane-bound Fab1 all produce antibodies higher than cells expressing membrane-bound Fab2 or membrane-bound Fab3. It became clear. Therefore, cells expressing an antibody gene having a splicing donor sequence inserted into the CH2 domain of the antibody constant region can be selected by the expression of the spliced membrane-bound Fab, and the selected cells was confirmed to produce antibodies.
  • Herceptin heavy chain expression vector 4D5 secreted / membrane-bound heavy chain expression vector 4D5TM
  • membrane-bound Fab Fragment expression vectors 4D5TM_Fab, 4D5TM_Fab1, 4D5TM_Fab2 and 4D5TM_Fab3 were introduced into CHO-K1 cells together with Herceptin's light chain expression vector 4D5 Lc to produce a transfectant, and cycloheximide (Cat. No. C4859, SIGMA) The drug selection was carried out.
  • CD opti CHO (Life Technologies) is added with L-Glutamine (Life Technologies) and cultured in a medium containing 3 mg / mL cycloheximide to select only cells that exhibit drug resistance. did. Cycloheximide-resistant CHO cells are stained with FITC-Protein A (Cat. No. 101011, Invitrogen) or Protein G, Alexa Fluor 488 conjugate (Cat. No. P11065, Invitrogen), and using FACSCalibur (BD Pharmigen) The fluorescence intensity on the cell surface was measured. Gates with fluorescence intensities of 10 2 to 10 4 were set to show the cell population (%) that reacted with each label (Table 7).
  • CHO-K1 introduced with secretory / membrane-bound Herceptin expression vector 4D5TM and membrane-bound Fab fragment expression vector compared to CHO-K1 into which host cell CHO-K1 and secreted Herceptin expression vector 4D5 were introduced. Both bound to both Protein A and Protein G. Moreover, since CHO-K1 introduced with 4D5TM bound most strongly to both Protein A and Protein G, it was confirmed that the membrane-bound IgG antibody was expressed efficiently and predominantly.
  • CHO-K1 introduced with membrane-bound Fab fragment expression vectors 4D5TM-Fab, 4D5TM-Fab1, 4D5TM-Fab2, and 4D5TM-Fab3 all have a binding activity against Protein A compared to CHO-K1 introduced with 4D5TM.
  • 4D5TM-Fab and 4D5TM-Fab1 decreased to about 1/2
  • 4D5TM-Fab2 and 4D5TM-Fab3 decreased to about 1/4.
  • Protein G the membrane-bound Fab fragment expression vector 4D5TM-Fab or 4D5TM-Fab1 was slightly reduced in binding amount compared to CHO-K1 into which 4D5TM was introduced, but 4D5TM-Fab2 or 4D5TM-Fab3 Protein G binding activity decreased to about 1/2.
  • cells introduced with 4D5TM expressing membrane-bound IgG and cells transfected with 4D5TM-Fab and 4D5TM-Fab1 expressing membrane-bound Fab fragments efficiently expressed IgG or Fab fragments.
  • the expressed Fab fragment has a reduced binding activity to Protein A.
  • cells introduced with 4D5TM-Fab2 or 4D5TM-Fab3 have a protein-A binding activity as well as a protein-G binding activity reduced, so that compared with cells introduced with 4D5TM-Fab and 4D5TM-Fab1, membrane-bound type The possibility that the expression level of the Fab fragment was low was revealed.
  • Membrane-bound IgG may be contaminated with secretory IgG antibody in the manufacturing process of antibody drugs, but it is difficult to separate even with Protein A column purification. Therefore, by using a cell that expresses a membrane-bound Fab fragment that does not bind to Protein A, contamination in the production process of the antibody drug can be prevented.
  • an expression vector for a target protein capable of simultaneously expressing a target protein and a protein in which the target protein or the target protein fragment and the transmembrane region are fused using a single gene is expressed.
  • SEQ ID NO: 1 Splicing donor sequence
  • SEQ ID NO: 2 Splicing donor sequence
  • SEQ ID NO: 3 Splicing donor sequence
  • SEQ ID NO: 4 Splicing acceptor sequence
  • SEQ ID NO: 5 Splicing acceptor sequence
  • SEQ ID NO: 6 Polypyrimidine sequence T / C8
  • SEQ ID NO: 7 Polypyrimidine sequence T / C15
  • SEQ ID NO: 8 Polypyrimidine sequence T / C25 SEQ ID NO: 9: OX40 L chain
  • SEQ ID NO: 10 CD98 / LAT1 H chain
  • SEQ ID NO: 11 BGH polyadenylation signal sequence
  • SEQ ID NO: 12 PDGFR transmembrane region
  • SEQ ID NO: 13 Synthetic construct
  • SEQ ID NO: 16 TM-R2 primer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un vecteur d'expression d'une protéine souhaitée qui peut être utilisée pour la production d'une composition protéique avec une efficacité élevée et en grande quantité et pour la production d'un médicament contenant une protéine d'une manière sûre, et un procédé de production d'une protéine souhaitée à l'aide du vecteur. Selon la présente invention, il devient possible de fournir : un vecteur d'expression d'une protéine souhaitée qui peut exprimer à la fois une protéine de fusion (une protéine de liaison à une membrane ou un fragment de la protéine de liaison à une membrane) d'une protéine souhaitée et un domaine transmembranaire et la protéine souhaitée en même temps ; une cellule ayant le vecteur introduit à l'intérieur de celle-ci ; un procédé de criblage pour une cellule ayant le vecteur introduit à l'intérieur de celle-ci ; un procédé d'expression à la fois de la protéine souhaitée et de la protéine de liaison à une membrane en même temps par l'introduction du vecteur à l'intérieur d'une cellule hôte ; une cellule apte à produire la protéine souhaitée, qui peut produire la protéine souhaitée à un taux élevé et peut être obtenue par criblage pour une cellule, dans laquelle le vecteur a été introduit pour exprimer la protéine de liaison à une membrane, par l'utilisation de la quantité d'expression de la protéine de liaison à une membrane en tant que mesure ; et un procédé de production de la protéine souhaitée à l'aide de la cellule.
PCT/JP2014/053730 2013-02-18 2014-02-18 Vecteur d'expression de protéine de liaison à une membrane Ceased WO2014126254A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-028515 2013-02-18
JP2013028515 2013-02-18

Publications (1)

Publication Number Publication Date
WO2014126254A1 true WO2014126254A1 (fr) 2014-08-21

Family

ID=51354252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/053730 Ceased WO2014126254A1 (fr) 2013-02-18 2014-02-18 Vecteur d'expression de protéine de liaison à une membrane

Country Status (1)

Country Link
WO (1) WO2014126254A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017508459A (ja) * 2014-02-28 2017-03-30 グレンマーク ファーマシューティカルズ， エセ．アー． ポリペプチドを発現する宿主細胞を選択するための発現構築物および方法
WO2017059243A3 (fr) * 2015-09-30 2017-06-08 Janssen Biotech, Inc. Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009537124A (ja) * 2006-05-17 2009-10-29 エフ．ホフマン−ラ ロシュ アーゲー ポリペプチド産生細胞
WO2009151605A1 (fr) * 2008-06-11 2009-12-17 Jn Biosciences Llc Vecteurs d’expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009537124A (ja) * 2006-05-17 2009-10-29 エフ．ホフマン−ラ ロシュ アーゲー ポリペプチド産生細胞
WO2009151605A1 (fr) * 2008-06-11 2009-12-17 Jn Biosciences Llc Vecteurs d’expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COOLIDGE, C. J. ET AL.: "Functional analysis of the polypyrimidine tract in pre-mRNA splicing", NUCLEIC ACIDS RESEARCH, vol. 25, no. 4, 1997, pages 888 - 896 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017508459A (ja) * 2014-02-28 2017-03-30 グレンマーク ファーマシューティカルズ， エセ．アー． ポリペプチドを発現する宿主細胞を選択するための発現構築物および方法
WO2017059243A3 (fr) * 2015-09-30 2017-06-08 Janssen Biotech, Inc. Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation
US10544229B2 (en) 2015-09-30 2020-01-28 Janssen Biotech, Inc. Agonistic antibodies specifically binding CD40 and methods of use
EA037882B1 (ru) * 2015-09-30 2021-05-31 Янссен Байотек, Инк. Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения

Similar Documents

Publication Publication Date Title
ES2682078T3 (es) Anticuerpo anti-TIM-3
JP5635912B2 (ja) 改善された哺乳動物発現ベクター及びその使用
JP5642549B2 (ja) 複数の核酸からのタンパク質発現
US11267899B2 (en) Afucosylated protein, cell expressing said protein and associated methods
US8399249B2 (en) Procedure for the generation of a high producer cell line for the expression of a recombinant anti-CD34 antibody
US20170158779A1 (en) Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US20100297697A1 (en) Methods for increasing protein titers
US9399671B2 (en) Method for producing proteins
IL258537B1 (en) Improved flare (flow cytometry attenuated reporter expression) technology for rapid bulk sorting
JP2011518790A (ja) ポリクローナルタンパク質を製造する方法
KR102058658B1 (ko) 단백질의 생산 방법
CN106255752A (zh) 表达构建体和用于选择表达多肽的宿主细胞的方法
WO2014126254A1 (fr) Vecteur d'expression de protéine de liaison à une membrane
US20190031752A1 (en) Method for Producing Antibodies
JP2025510719A (ja) 選択マーカーとしての新規グルタミン合成酵素変異体
CN104968791B (zh) 优化的高产率表达多肽的表达盒
Aebischer-Gumy et al. Alternative splicing for tuneable expression of protein subunits at desired ratios
JP6661549B2 (ja) ポリペプチドの産生の方法
Chinakarapong et al. Intracellular Antibody Levels Predict Secretion Efficiency in HEK293T Cells Expressing a Chimeric Anti‐CD99 Antibody from a Single‐Expression Plasmid
CN120322561A (zh) 新型转座酶系统
WO2015033086A1 (fr) Produit de recombinaison d'adn
HK1232562A1 (en) Expression constructs and methods for selecting host cells expressing polypeptides
HK1232253B (zh) 生产多肽的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14751846

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14751846

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP